Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.
Childhood growth and development
Diarrhoeal diseases
Disease burden
Enterotoxigenic Escherichia coli (ETEC)
Vaccine research
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
05
02
2021
revised:
06
04
2021
accepted:
09
04
2021
pubmed:
10
5
2021
medline:
7
8
2021
entrez:
9
5
2021
Statut:
ppublish
Résumé
Diarrhoeal disease attributable to enterotoxigenic Escherichia coli (ETEC) causes substantial morbidity and mortality predominantly in paediatric populations in low- and middle-income countries. In addition to acute illness, there is an increasing appreciation of the long-term consequences of enteric infections, including ETEC, on childhood growth and development. Provision of potable water and sanitation and appropriate clinical care for acute illness are critical to reduce the ETEC burden. However, these interventions are not always practical and may not achieve equitable and sustainable coverage. Vaccination may be the most cost-effective and equitable means of primary prevention; however, additional data are needed to accelerate the investment and guide the decision-making process for ETEC vaccines. First, to understand and quantify the ETEC disease burden, additional data are needed on the association between ETEC infection and physical and cognitive stunting as well as delayed educational attainment. Furthermore, the role of inappropriate or inadequate antibiotic treatment of ETEC-attributable diarrhoea may contribute to the development of antimicrobial resistance (AMR) and needs further elucidation. An ETEC vaccine that mitigates acute diarrhoeal illness and minimizes the longer-term disease manifestations could have significant public health impact and be a cost-effective countermeasure. Herein we review the ETEC vaccine pipeline, led by candidates compatible with the general parameters of the Preferred Product Characteristics (PPC) recently developed by the World Health Organization. Additionally, we have developed an ETEC Vaccine Development Strategy to provide a framework to underpin priority activities for researchers, funders and vaccine manufacturers, with the goal of addressing globally unmet data needs in the areas of research, product development, and policy, as well as commercialization and delivery. The strategy also aims to guide prioritization and co-ordination of the priority activities needed to minimize the timeline to licensure and use of ETEC vaccines, especially in in low- and middle-income countries, where they are most urgently needed.
Identifiants
pubmed: 33965254
pii: S0264-410X(21)00453-9
doi: 10.1016/j.vaccine.2021.04.018
pmc: PMC8273896
pii:
doi:
Substances chimiques
Escherichia coli Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4266-4277Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Références
Lancet Glob Health. 2019 Mar;7(3):e321-e330
pubmed: 30784633
J Health Popul Nutr. 2004 Dec;22(4):370-82
pubmed: 15663170
Vaccine. 2018 Oct 29;36(45):6606-6614
pubmed: 30314912
Clin Infect Dis. 2020 Jun 27;:
pubmed: 32592580
Lancet Infect Dis. 2018 Nov;18(11):1229-1240
pubmed: 30266330
Infect Immun. 2019 Jan 24;87(2):
pubmed: 30510102
Expert Rev Vaccines. 2005 Dec;4(6):807-12
pubmed: 16372876
Pediatr Infect Dis J. 2006 Jun;25(6):513-20
pubmed: 16732149
Lancet. 1991 Nov 23;338(8778):1285-9
pubmed: 1682684
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Expert Rev Vaccines. 2008 Aug;7(6):795-804
pubmed: 18665777
PLoS Negl Trop Dis. 2019 Nov 22;13(11):e0007825
pubmed: 31756188
PLoS Negl Trop Dis. 2017 Jan 19;11(1):e0005291
pubmed: 28103236
PLoS Negl Trop Dis. 2020 Aug 10;14(8):e0008520
pubmed: 32776938
J Infect Dis. 2011 Jul 1;204(1):60-4
pubmed: 21628659
Clin Microbiol Rev. 2005 Jul;18(3):465-83
pubmed: 16020685
Vaccine. 2019 Aug 7;37(34):4800-4804
pubmed: 31358239
PLoS One. 2020 Aug 12;15(8):e0236703
pubmed: 32785284
Lancet. 2020 Aug 22;396(10250):517-518
pubmed: 32730742
Infect Immun. 2019 Oct 18;87(11):
pubmed: 31427449
Vaccine. 2017 Jun 8;35(26):3355-3363
pubmed: 28504192
Vaccine. 2013 May 7;31(20):2457-64
pubmed: 23541621
mSystems. 2019 Jan 15;4(1):
pubmed: 30944874
Vaccine. 2017 Dec 14;35(49 Pt A):6790-6792
pubmed: 28705515
EBioMedicine. 2017 Apr;18:109-117
pubmed: 28396264
J Infect Dis. 2019 Jun 5;220(1):151-162
pubmed: 30768135
Vaccine. 2019 Aug 7;37(34):4768-4774
pubmed: 31358236
Vaccine. 2019 Sep 3;37(37):5645-5656
pubmed: 30473185
Infect Immun. 2018 Jun 21;86(7):
pubmed: 29661930
Vaccine. 2014 Dec 12;32(52):7077-84
pubmed: 25444830
Microbiome. 2020 Sep 11;8(1):130
pubmed: 32917289
Lancet Glob Health. 2018 Dec;6(12):e1309-e1318
pubmed: 30287127
J Clin Invest. 2018 Aug 1;128(8):3298-3311
pubmed: 29771685
mSphere. 2018 Aug 1;3(4):
pubmed: 30068560
Expert Rev Vaccines. 2014 May;13(5):631-9
pubmed: 24702311
NPJ Vaccines. 2019 Aug 28;4:37
pubmed: 31482013
BMC Public Health. 2011 Apr 13;11 Suppl 3:S15
pubmed: 21501432
Emerg Infect Dis. 2005 Jul;11(7):1104-7
pubmed: 16022790
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29055-29062
pubmed: 33139570
Lancet Infect Dis. 2020 Feb;20(2):208-219
pubmed: 31757774
Vaccine. 2017 Jan 23;35(4):552-556
pubmed: 28017433
Vaccine. 2011 Aug 26;29(37):6167-78
pubmed: 21723899
Sci Rep. 2017 Sep 6;7(1):10649
pubmed: 28878367
Adv Nutr. 2019 Mar 1;10(2):196-204
pubmed: 30801614
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Infect Immun. 2006 Apr;74(4):2245-58
pubmed: 16552055
NPJ Vaccines. 2020 Mar 27;5:30
pubmed: 32257392
Vaccines (Basel). 2020 Nov 16;8(4):
pubmed: 33207794
Infect Immun. 1975 Sep;12(3):656-67
pubmed: 1100526
Lancet Glob Health. 2018 Mar;6(3):e255-e269
pubmed: 29433665
Infect Immun. 2009 Dec;77(12):5206-15
pubmed: 19737904
PLoS Negl Trop Dis. 2019 Jan 4;13(1):e0007037
pubmed: 30608930
Future Microbiol. 2018 Jan;13:97-118
pubmed: 29218997
PLoS One. 2018 Aug 30;13(8):e0202178
pubmed: 30165370
J Clin Invest. 2008 Apr;118(4):1277-90
pubmed: 18382740
Lancet Glob Health. 2019 May;7(5):e568-e584
pubmed: 31000128
Lancet. 2016 Jan 30;387(10017):475-90
pubmed: 26869575
Vaccine. 2018 Oct 29;36(45):6695-6702
pubmed: 30269917
Lancet. 2007 Jan 13;369(9556):145-57
pubmed: 17223478
Lancet Glob Health. 2015 Sep;3(9):e564-75
pubmed: 26202075
Vaccine X. 2019 Sep 20;3:100043
pubmed: 31687662
Lancet Glob Health. 2020 Jun;8(6):e742-e743
pubmed: 32446336
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Vaccine. 2016 Jun 3;34(26):2880-2886
pubmed: 26988259
Lancet Infect Dis. 2018 Jun;18(6):e204-e213
pubmed: 29146178
Infect Immun. 1979 Mar;23(3):729-36
pubmed: 378834
Expert Rev Vaccines. 2012 Jun;11(6):677-94
pubmed: 22873126
Nat Genet. 2014 Dec;46(12):1321-6
pubmed: 25383970
J Infect Dis. 2010 Sep 1;202 Suppl:S12-22
pubmed: 20684691
Am J Trop Med Hyg. 2011 Mar;84(3):451-5
pubmed: 21363985
Am J Trop Med Hyg. 2002 May;66(5):590-3
pubmed: 12201596
Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):220-9
pubmed: 23229327
Am J Trop Med Hyg. 1999 Nov;61(5):707-13
pubmed: 10586898
Vaccine. 2017 Jul 13;35(32):3966-3973
pubmed: 28625524
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22727-22735
pubmed: 32868442
Microbes Infect. 2010 Feb;12(2):89-98
pubmed: 19883790
Infect Immun. 2008 May;76(5):2106-12
pubmed: 18285493
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
J Infect Dis. 1998 Jan;177(1):88-96
pubmed: 9419174
Future Microbiol. 2018 Jul;13:1055-1070
pubmed: 29926747
Vaccine. 2015 Feb 18;33(8):946-53
pubmed: 25500172
Infect Immun. 2018 Feb 20;86(3):
pubmed: 29263112
Vaccine. 2019 Mar 28;37(14):1978-1986
pubmed: 30797634